abbv-621

Recombinant proteinexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Mar 29, 2017 (NCT03082209)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • abbv-621

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04570631Phase 1Nov 5, 2020AbbVie
NCT03082209Phase 1Mar 29, 2017AbbVie
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AbbVieFor profit2212017
1 organizations
Page 1 / 1